QUAKERTOWN, PA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)PANCREATIC CANCER CURE FOUNDATION, founded in 2016, is a micro nonprofit in the Medical Research sector that reported $78K in total revenue in fiscal year 2023. Revenue grew 11% year-over-year, indicating healthy expansion. Expenses of $73K left a modest 6% surplus.
PANCREATIC CANCER CURE FOUNDATION'S MISSION IS TO RAISE MONEY AND DISTRIBUTE FUNDING PRIMARILY TOWARDS PANCREATIC CANCER RESEARCH AND COMPASSIONATE CARE INITIATIVES, AND, TO A LESSER EXTENT, AWARENESS AND ADVOCACY EFFORTS.
$30,000 IN FUNDING WAS PROVIDED TO THE PANCREAS, BILIARY, & RELATED CANCER CENTER AT SIDNEY KIMMEL CANCER CENTER AT JEFFERSON UNIVERSITY, AN NCI-DESIGNATED FACILITY. FUNDING SUPPORTS RESEARCH TO...
$30,000 IN FUNDING WAS PROVIDED TO THE PANCREAS, BILIARY, & RELATED CANCER CENTER AT SIDNEY KIMMEL CANCER CENTER AT JEFFERSON UNIVERSITY, AN NCI-DESIGNATED FACILITY. FUNDING SUPPORTS RESEARCH TO IMPROVE EARLY DETECTION OF PANCREATIC CANCER AND DEVELOP MORE EFFECTIVE SCREENING PROCEDURES. THIS FACILITY IS LEADING INVESTIGATIONS INTO GENETIC, ENVIRONMENTAL, AND LIFESTYLE LINKS TO PANCREATIC AND RELATED CANCERS, INCLUDING NOVEL APPROACHES TO INDIVIDUALIZED THERAPY BASED ON MOLECULAR GENETIC FEATURES OF TUMORS. $2,000 IN FUNDING WAS USED FOR JEFFERSON'S "COMPASSIONATE CARE" INITIATIVES.
FUNDING WAS PROVIDED TO ST. LUKE'S CANCER CENTER FOR "COMPASSIONATE CARE" DISTRIBUTION TO FINANCIALLY COMPROMISED PANCREATIC CANCER PATIENTS TO COVER COSTS SUCH AS TRANSPORTATION, UTILITIES, ETC.
FUNDING WAS PROVIDED TO FOX CHASE INSTITUTE FOR CANCER RESEARCH TO ADVANCE RESEARCH BEING CONDUCTED BY THE CUIKERMAN LAB/MARVIN & CONCETTA GREENBURG PANCREATIC CANCER INSTITUTE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $77,645 | $69,855 | +0.1% |
| Expenses | $73,144 | $79,533 | -0.1% |
| Net Income | $4,501 | $-9,678 | -1.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MICHAEL CYGAN | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| ANTHONY CYGAN | VICE PRESIDENT | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| DAVID CYGAN | SECRETARY | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| JANE CYGAN | TREASURER | 10.00 |
Officer
Director
|
$0 | $0 | $0 |
| STEPHEN CYGAN | PRESIDENT | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| NATHAN CYGAN | DIRECTOR | 3.00 |
Director
|
$0 | $0 | $0 |
| GREGORY CYGAN | DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| MARLENE MAYZA | DIRECTOR | 3.00 |
Director
|
$0 | $0 | $0 |
| CELESTE VAUGHN | DIRECTOR | 8.00 |
Director
|
$0 | $0 | $0 |
| LAURA DEPENBUSCH | DIRECTOR | 8.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $77,645 | $73,144 | $6,424 | $4,501 |
| 2023 | $69,855 | $79,533 | $1,923 | $-9,678 |
| 2022 | $79,330 | $76,672 | $11,601 | $2,658 |
| 2021 | $77,288 | $78,260 | $8,943 | $-972 |
| 2020 | $38,209 | $39,906 | $9,915 | $-1,697 |
| 2019 | $55,856 | $69,146 | $11,612 | $-13,290 |
| 2018 | $41,372 | $19,784 | $24,902 | $21,588 |
Compare PANCREATIC CANCER CURE FOUNDATION with other nonprofits in Pennsylvania and across the country.